01651: Serum Antibody Reactivity Profiling for Canine Lymphoma Detection and Monitoring
Grant Status: Closed
Diagnosis of canine lymphoma is complicated by the lack of a non-invasive test. Few validated biomarkers for canine lymphoma exist. We are addressing this need through our Immunosignaturing platform by demonstrating that canine lymphoma patients can be distinguished from healthy individuals. Two diagnostics of great utility to improve the quality of life of these patients following chemotherapy would be the ability to determine if a patient has entered remission and the ability to detect recurrence prior to current clinical determination. To address the first question of detecting remission, we have established a potential mechanism to determine if the patient has entered remission. Second we have established a potential mechanism to prognostically determine at the time of diagnosis whether the dog will relapse within 4 months of the start of remission.
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.